USPTO Examiner KIM YUNSOO - Art Unit 1641

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19198946Subcutaneous Formulations Of Anti-CD38 Antibodies And Their UsesMay 2025January 2026Allow820NoNo
19194986IMMUNOTHERAPEUTIC COMPOSITION FOR PREVENTION OF OBESITY, NONALCOHOLIC FATTY LIVER DISEASE AND HYPERTRIGLYCERIDEMIA, AND METHODS OF USE AND PREPARATION THEREOFApril 2025October 2025Allow611YesNo
19061157METHODS OF TREATING INFLAMMATORY AND/OR ALLERGIC DISORDERS WITH NORKETOTIFENFebruary 2025December 2025Abandon911NoNo
19048808Production of Biosimilar Ustekinumab In CHO CellsFebruary 2025March 2026Allow1321YesNo
18774646COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIESJuly 2024April 2025Allow920YesNo
18774629COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIESJuly 2024March 2025Allow820YesNo
18774608COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIESJuly 2024January 2025Allow610YesNo
18764499ENHANCED PEPTIDE CONSTRUCTS FOR ALBUMIN BINDINGJuly 2024May 2025Abandon1011YesNo
18444471COMPOSITIONS COMPRISING PHARMACEUTICALLY ACCEPTABLE SALTS OF AMYLIN ANALOGS AND USES THEREOFFebruary 2024November 2024Allow911YesNo
18439344Nano-sized Chitosan/VS2 nanocomposite like flowers for Antimicrobial ApplicationsFebruary 2024November 2024Allow911YesNo
18439336Method for Making Nano-sized Chitosan/VS2 NanocompositesFebruary 2024October 2024Allow820NoNo
18507324Nano-sized Chitosan/VS2 nanocomposite like flowers for Potential Pharmaceutical ApplicationsNovember 2023July 2024Allow921YesNo
18341437COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIESJune 2023May 2024Allow1011YesNo
18324097Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use ThereofMay 2023March 2024Allow1021NoNo
18305919Production of Biosimilar Ustekinumab in CHO CellsApril 2023June 2024Allow1320YesNo
18300064PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USEApril 2023January 2024Allow911YesNo
18117995COMPOSITIONS COMPRISING PEPTIDES THAT BLOCK TRANSMISSION OF ORTHOTOSPOVIRUSESMarch 2023July 2025Allow2811NoNo
18105772Stabilized Formulations Containing Anti-IL-33 AntibodiesFebruary 2023January 2026Allow3520NoNo
18162791STABLE ANTIBODY FORMULATIONFebruary 2023December 2025Allow3510NoNo
18161036PROTEIN-TYPE NANOPARTICLES, PREPARATION METHODS, AND APPLICATION THEREOFJanuary 2023December 2023Allow1121NoNo
18086031HIGH CONCENTRATION ANTI-C5 ANTIBODY FORMULATIONSDecember 2022February 2024Allow1411YesNo
18002248COMBINING IPSC DERIVED EFFECTOR CELL TYPES FOR IMMUNOTHERAPY USEDecember 2022December 2024Allow2421YesYes
17926313ANTIBODY-CONTAINING FORMULATIONNovember 2022October 2025Allow3531YesNo
18054101COMPOSITIONS AND METHODS FOR ENHANCING TRIPLEX AND NUCLEASE-BASED GENE EDITINGNovember 2022November 2024Abandon2421NoNo
17959272Modified Clostridial Neurotoxins as Vaccine and Conjugate Vaccine PlatformsOctober 2022December 2025Allow3911YesNo
17913457ANTIBODIESSeptember 2022March 2026Abandon4101NoNo
17911167PHARMACEUTICAL LIQUID COMPOSITION HAVING INCREASED STABILITYSeptember 2022February 2026Abandon4110NoNo
17890866PHARMACEUTICAL FORMULATIONS OF TNF-ALPHA ANTIBODIESAugust 2022July 2025Abandon3510NoNo
17864622Immunoglobulin Preparation and Storage System for an Immunoglobulin PreparationJuly 2022October 2025Allow3920YesNo
17863587METHOD FOR PURIFYING IMMUNOGLOBULIN SOLUTIONSJuly 2022June 2025Abandon3501NoNo
17808029ANTIBODY FORMULATIONSJune 2022July 2025Abandon3701NoNo
17786251IGG:TGFBETARII FUSION PROTEIN COMPOSITIONJune 2022January 2026Abandon4301NoNo
17831645EXCIPIENT COMPOUNDS FOR PROTEIN PROCESSINGJune 2022June 2025Abandon3601NoNo
17832463METHODS AND FORMULATIONS FOR REDUCING RECONSTITUTION TIME OF LYOPHILIZED POLYPEPTIDESJune 2022June 2025Allow3620YesNo
17738870ROOM TEMPERATURE STABLE LYOPHILIZED PROTEINMay 2022September 2025Allow4021NoNo
17773538METHODS, COMPOSITIONS, AND VACCINES FOR TREATING A VIRUS INFECTIONApril 2022September 2025Abandon4131NoYes
17732224Thermostable Vaccine Compositions and Methods of Preparing The SameApril 2022June 2025Allow3811YesNo
17731718FORMULATION CONTAINING TLR AGONIST AND METHODS OF USEApril 2022July 2025Allow3911YesNo
17731671FORMULATION CONTAINING TLR AGONIST AND METHODS OF USEApril 2022May 2025Allow3721YesNo
17726741HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)April 2022March 2025Abandon3510NoNo
17690437METHODS PROVIDING A THERAPEUTIC MACROMOLECULE AND SYNTHETIC NANOCARRIERS COMPRISING IMMUNOSUPPRESSANT LOCALLY AND CONCOMITANTLY TO REDUCE BOTH TYPE 1 AND TYPE IV HYPERSENSITIVITYMarch 2022July 2025Allow4020NoNo
17675488USE OF THE IL-1BETA BINDING ANTIBODY CANAKINUMAB FOR TREATING OR ALLEVIATING SYMPTOMS OF PULMONARY SARCOIDOSISFebruary 2022February 2025Abandon3601NoNo
17673149PHARMACEUTICAL FORMULATIONS FOR ADALIMUMABFebruary 2022July 2025Allow4120YesYes
17584286PROTEIN FORMULATIONS AND METHODS OF MAKING SAMEJanuary 2022February 2025Abandon3601NoNo
17572350Production of Biosimilar Ustekinumab In CHO CellsJanuary 2022March 2025Abandon3811NoNo
17564976Methods and Devices for the Enrichment of Immunoglobulin from BloodDecember 2021March 2026Allow5040YesNo
17562480CXCR5 ANTIBODY FORMULATIONSDecember 2021January 2026Allow4940NoNo
17554758METHODS FOR ENHANCED REMOVAL OF IMPURITIES DURING PROTEIN A CHROMATOGRAPHYDecember 2021September 2025Allow4521NoNo
17552392METHODS FOR PROVIDING POLYMERIC SYNTHETIC NANOCARRIERS FOR GENERATING ANTIGEN-SPECIFIC TOLERANCE IMMUNE RESPONSESDecember 2021May 2025Abandon4111NoNo
17542632VISCOSITY REDUCTION OF HIGHLY CONCENTRATED PROTEIN FORMULATIONSDecember 2021December 2024Allow3621NoNo
17457456USE OF AMINO ACIDS AS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS CONTAINING HIGH CONCENTRATIONS OF PROTEIN-BASED THERAPEUTIC AGENTSDecember 2021May 2024Abandon2911NoNo
17534218NANOENCAPSULATION OF ANTIGEN-BINDING MOLECULESNovember 2021August 2024Abandon3301NoNo
17455713FORMULATIONS OF MONOCLONAL ANTIBODIESNovember 2021February 2025Abandon3930NoNo
17519141HIGH CONCENTRATION IMMUNOGLOBULIN COMPOSITION FOR PHARMACEUTICAL APPLICATIONNovember 2021October 2024Allow3521NoNo
17608546PHARMACEUTICAL FORMULATIONS CONTAINING CD80 EXTRACELLULAR DOMAIN-FC FUSION PROTEINSNovember 2021March 2026Allow5221YesNo
17514957PROCESS FOR PREPARING AN IMMUNOGLOBULIN PREPARATIONOctober 2021September 2024Allow3420NoNo
17503759Novel Formulations Which Stabilize Low Dose Antibody CompositionsOctober 2021April 2025Abandon4121NoNo
17487801COMPOSITION COMPRISING CATALASE, PREPARATION METHOD AND USE THEREOF AND METHOD FOR KILLING TUMOR CELLSSeptember 2021September 2025Allow4841YesNo
17437634PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-LINGO-1 ANTIBODIESSeptember 2021May 2025Abandon4401NoNo
17470270METHODS AND COMPOSITIONS FOR TARGETING T-CELL CANCERSSeptember 2021June 2024Abandon3301NoNo
17460979IMMUNOGENIC COMPOSITION FOR THE TREATMENT OF CANCER AND METHODS OF PREPARING THE SAMEAugust 2021March 2024Allow3010NoNo
17400880CD154 PEPTIDES AND METHODS OF REDUCING INFLAMMATIONAugust 2021February 2026Allow5421NoNo
17393888METHODS FOR PREPARING ALUMINUM PRECIPITATE COMPOUNDS FOR USE IN THERAPEUTICS AND VACCINESAugust 2021January 2025Allow4231YesNo
17391663NANOPARTICLES, CONTROLLED-RELEASE DOSAGE FORMS, AND METHODS FOR DELIVERING AN IMMUNOTHERAPEUTIC AGENTAugust 2021January 2025Abandon4221NoNo
17387239PHOSPHOSERINE CONTAINING COMPOSITIONS FOR IMMUNE TOLERANCE INDUCTIONJuly 2021September 2025Abandon4921NoYes
17386385COMPOSITIONS AND METHODS FOR STABILIZING PROTEIN-CONTAINING FORMULATIONSJuly 2021November 2023Allow2820NoNo
17423927OIL/SURFACTANT MIXTURES FOR SELF-EMULSIFICATIONJuly 2021September 2025Abandon5001NoNo
17378025STABLE LIQUID ANTIBODY FORMULATIONJuly 2021February 2024Abandon3110NoNo
17350781LIPOSOME COMPOSITIONS COMPRISING PAM2CYS OR PAM3CYS ADJUVANT AND METHODS FOR INDUCING A HUMORAL IMMUNE RESPONSEJune 2021August 2024Abandon3820NoNo
17332521EXCIPIENT COMPOUNDS FOR PROTEIN PROCESSINGMay 2021November 2024Abandon4221NoNo
17328408Method for the reduction of host cell proteins in affinity chromatographyMay 2021July 2025Allow4920YesNo
17320693STABILIZED ANTIBODY COMPOSITIONSMay 2021January 2024Allow3220NoNo
17316585Thermostable Vaccine Compositions and Methods of Preparing sameMay 2021May 2024Allow3611YesNo
17291956METHOD OF IMPROVING BLOOD KINETICS OF PEPTIDEMay 2021November 2025Allow5431YesNo
17291194ANTI-PTK7 IMMUNE CELL CANCER THERAPYMay 2021March 2025Abandon4611NoNo
17246288METHODS AND COMPOSITIONS FOR INCREASING IDURONATE 2-SULFATASE ACTIVITY IN THE CNSApril 2021March 2024Allow3420YesNo
17233008Composition Comprising an AntibodyApril 2021July 2024Allow3920YesNo
17225887Stabilized Formulations Containing Anti-Interleukin-6 Receptor (IL-6R) AntibodiesApril 2021April 2024Allow3620NoNo
17224900FORMULATIONS OF MONOCLONAL ANTIBODIESApril 2021October 2024Abandon4321NoNo
17282382Multimeric Hybrid Fc Proteins for Replacement of IVIGApril 2021September 2025Allow5331YesNo
17211459METHODS OF ADMINISTERING IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE LIFE AND THERAPEUTIC MACROMOLECULES FOR THE INDUCTION OF IMMUNE TOLERANCEMarch 2021January 2024Abandon3410NoNo
17211399AQUEOUS PHARMACEUTICAL FORMULATIONSMarch 2021December 2023Abandon3301NoNo
17208300HUMAN iPSC-DERIVED BRAIN ORGANOIDS AND USES THEREOFMarch 2021August 2025Allow5321YesNo
17200552CONJUGATE VACCINE TARGETING A DISEASE-CAUSING BIOLOGICAL PROTEINMarch 2021March 2024Allow3611YesNo
17197603COMPOSITIONS OF IL-6/IL-6R ANTIBODIES AND METHODS OF USE THEREOFMarch 2021November 2024Abandon4421NoNo
17191589IMMUNOGLOBULIN FORMULATION AND METHOD OF PREPARATION THEREOFMarch 2021September 2024Abandon4321NoNo
17179223NOVEL BISPECIFIC ANTIGEN BINDING MOLECULES CAPABLE OF SPECIFIC BINDING TO CD40 AND TO FAPFebruary 2021July 2024Allow4121YesNo
17177022HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONSFebruary 2021November 2023Abandon3301NoNo
17175162EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONSFebruary 2021August 2023Allow3061YesNo
17170667COMPOSITIONS AND METHODS FOR TREATING POMPE DISEASEFebruary 2021November 2024Allow4531YesNo
17165704PROTEIN-NANOPARTICLE CONJUGATE PURIFICATION METHODSFebruary 2021October 2023Allow3220NoNo
17155432STABLE ANTIBODY FORMULATIONJanuary 2021February 2025Allow4950YesNo
17154108METHODS OF PURIFICATIONJanuary 2021August 2025Abandon5521NoNo
17152054COMPOSITIONS COMPRISING AN ANTI-C5 ANTIBODYJanuary 2021October 2023Abandon3320NoNo
17260334FCRN ANTIBODY COMPOSITIONSJanuary 2021April 2025Allow5121YesNo
17141690CLEAVED HIGH MOLECULE WEIGHT KININOGEN (HMWK) ANTIBODIES AND METHODS OF USINGJanuary 2021August 2025Allow5512YesNo
17141271NOVEL ANTIGEN BINDING DIMER-COMPLEXES, METHODS OF MAKING/AVOIDING AND USES THEREOFJanuary 2021July 2025Allow5560YesNo
17254508METHODS OF PRODUCING ANTI-C5 ANTIBODIESDecember 2020April 2025Allow5120NoNo
17128736METHOD FOR TREATMENT OF A LEUKOCYTE RELATED DISEASE BY DELIVERY OF NUCLEIC ACID MOLECULES TO LEUKOCYTES USING TARGETED LIPID PARTICLESDecember 2020April 2024Allow4021YesNo
17251122MULTI-SPECIFIC ANTIBODY CONSTRUCTSDecember 2020July 2025Allow5531YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KIM, YUNSOO.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
9
Examiner Affirmed
4
(44.4%)
Examiner Reversed
5
(55.6%)
Reversal Percentile
81.1%
Higher than average

What This Means

With a 55.6% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
48
Allowed After Appeal Filing
15
(31.2%)
Not Allowed After Appeal Filing
33
(68.8%)
Filing Benefit Percentile
47.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 31.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner KIM, YUNSOO - Prosecution Strategy Guide

Executive Summary

Examiner KIM, YUNSOO works in Art Unit 1641 and has examined 206 patent applications in our dataset. With an allowance rate of 78.2%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 46 months.

Allowance Patterns

Examiner KIM, YUNSOO's allowance rate of 78.2% places them in the 46% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by KIM, YUNSOO receive 3.01 office actions before reaching final disposition. This places the examiner in the 87% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by KIM, YUNSOO is 46 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +38.1% benefit to allowance rate for applications examined by KIM, YUNSOO. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 23.0% of applications are subsequently allowed. This success rate is in the 30% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 57.8% of cases where such amendments are filed. This entry rate is in the 84% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 120.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 81% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 76.9% of appeals filed. This is in the 68% percentile among all examiners. Of these withdrawals, 56.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 60.5% are granted (fully or in part). This grant rate is in the 65% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 6.3% of allowed cases (in the 88% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.2% of allowed cases (in the 63% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.